Skip to main content
. 2023 Oct 26;11(11):1644. doi: 10.3390/vaccines11111644

Figure 1.

Figure 1

Longitudinal S1-RBD binding antibody response is shown for 1918 immunocompetent adult individuals across two years (104 weeks) from a large academic medical center cohort. The orange line represents those with prior infection at the time of vaccination and the blue line those with no prior infection. All completed a full regimen of primarily Pfizer BNT162b2 (73.5%), Moderna (20.5%), or other vaccines (6%). The median peak response (between prior infected and uninfected) is observed to be 30,199 AU/mL, corresponding to 4288 BAU/mL, and the peak prior uninfected response is 15,958 AU/mL or 2266 BAU/mL. The latter may better serve as a more conservative target for an expected immunocompetent response. A later rise in response is observed between 48 to 88 weeks, corresponding to booster doses and/or potential reinfection events. The dashed green line represents the threshold for positivity of the test employed. The majority of vaccinees remained above the positive threshold for the entire observation period.